Research.Patient.info

Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation research hub

1 indexed studies · 0 currently recruiting

ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Phase Ib/II, Multi-Center, Open-Label Study to Evaluate the Safety/Tolerability, Pharmacokinetics, and Efficacy of GFH925 in Combination with Cetuximab in Previously Untreated Advanced NSCLC Harboring KRAS G12C Mutation
This study looks at a new combination treatment for a specific type of advanced lung cancer that hasn't been treated before. It aims to see how safe and effective the new treatment, made up of two drugs, is for patients with a particular gene change.
Italy · Spain · France